tirzepatide vs semaglutide study NEJM recently published a pivotal comparing “Tirzepatide” and “ Semaglutide” for the Treatment of Obesity Tirzepatide vs Semaglutide: Key Weight

42 Medullary thyroid cancer There is a theoretical increased risk of medullary thyroid cancer (MTC) as preclinical studies showed a link between GLP-1 receptor agonism to the development of C-cell hyperplasia and MTC in rats and mice

Future waiver approvals and CMS guidance will provide additional insight into the waiver priorities and financing approach of the new Trump administration

This layered architecture is not accidental

Because of rare thyroid tumours seen in animal studies, these drugs are avoided in people with a history of medullary thyroid carcinoma or MEN2

In patients with obesity-related hormonal imbalancesparticularly those with polycystic ovary syndrome (PCOS) or metabolic syndromesignificant weight loss can lead to improvements in acne severity through normalization of insulin and androgen levels

Blood Glucose and HbA1c Changes Observed in the Trial The 12 mg dose produced mean HbA1c reductions of approximately 2.2 percentage points (~24 mmol/mol) at 24 weeks, with some participants reaching HbA1c levels below the 48 mmol/mol diagnostic threshold for type 2 diabetes